Share Email Print

Journal of Biomedical Optics

Quantifying the cerebral metabolic rate of oxygen by combining diffuse correlation spectroscopy and time-resolved near-infrared spectroscopy
Format Member Price Non-Member Price
PDF $20.00 $25.00

Paper Abstract

Preterm infants are highly susceptible to ischemic brain injury; consequently, continuous bedside monitoring to detect ischemia before irreversible damage occurs would improve patient outcome. In addition to monitoring cerebral blood flow (CBF), assessing the cerebral metabolic rate of oxygen (CMRO 2 ) would be beneficial considering that metabolic thresholds can be used to evaluate tissue viability. The purpose of this study was to demonstrate that changes in absolute CMRO 2 could be measured by combining diffuse correlation spectroscopy (DCS) with time-resolved near-infrared spectroscopy (TR-NIRS). Absolute CBF was determined using bolus-tracking TR-NIRS to calibrate the DCS measurements. Cerebral venous blood oxygenation (SvO 2 ) was determined by multiwavelength TR-NIRS measurements, the accuracy of which was assessed by directly measuring the oxygenation of sagittal sinus blood. In eight newborn piglets, CMRO 2 was manipulated by varying the anesthetics and by injecting sodium cyanide. No significant differences were found between the two sets of SvO 2 measurements obtained by TR-NIRS or sagittal sinus blood samples and the corresponding CMRO 2 measurements. Bland–Altman analysis showed a mean CMRO 2 difference of 0.0268±0.8340  mL O 2 /100  g/min between the two techniques over a range from 0.3 to 4 mL O 2 /100  g/min .

Paper Details

Date Published: 6 February 2013
PDF: 10 pages
J. Biomed. Opt. 18(2) 027007 doi: 10.1117/1.JBO.18.2.027007
Published in: Journal of Biomedical Optics Volume 18, Issue 2
Show Author Affiliations
Kyle Verdecchia, Lawson Health Research Institute (Canada)
Mamadou Diop, Lawson Health Research Institute (Canada)
Ting-Yim Lee, Robarts Research Institute (Canada)
Keith St. Lawrence, Lawson Health Research Institute (Canada)

© SPIE. Terms of Use
Back to Top